drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A subcutaneous, full-length humanized bispecific IgG1 antibody (T-cell–redirecting biologic) that binds CD20 on B cells and CD3 on T cells, bringing T cells into contact with malignant B cells to trigger TCR/CD3 activation, immune synapse formation, cytokine release, and perforin/granzyme-mediated cytotoxicity; depletes CD20+ B cells. Step-up dosing: 5 mg C1D1; 45 mg C1D8 and C1D15; then 45 mg on Day 1 of Cycles 2–8 (21-day cycles).
nci_thesaurus_concept_id
C129691
nci_thesaurus_preferred_term
Mosunetuzumab
nci_thesaurus_definition
A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.
drug_mesh_term
Mosunetuzumab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized bispecific IgG1 antibody that binds CD20 on B cells and CD3 on T cells to physically redirect and activate T cells against CD20+ malignant B cells, inducing immune synapse formation, cytokine release, and perforin/granzyme-mediated cytotoxicity leading to B-cell depletion.
drug_name
Mosunetuzumab
nct_id_drug_ref
NCT06569680